MIST Stock Forecast: Milestone Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Milestone Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Milestone Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (87): Analysts have, on balance, been raising their forecasts.
Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MIST stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MIST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $6.00 |
| 16 Nov 2026 | Piper Sandler | Maintains | Overweight | $7.00 → $3.00 |
| 16 Nov 2026 | TD Cowen | Maintains | Buy | $8.00 → $5.00 |
| 3 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 20 Aug 2026 | Cantor Fitzgerald | Initiates | Overweight | $3.00 |
| 14 May 2026 | Wells Fargo | Maintains | Overweight | $8.00 → $7.00 |
| 6 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 15 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Dec 2025 | TD Cowen | Upgrade | Buy | — |
| 11 Sept 2025 | Wells Fargo | Initiates | Overweight | — |
| 5 June 2025 | HC Wainwright & Co. | Assumes | Buy | $5.00 |
| 1 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Aug 2024 | Rodman & Renshaw | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MIST.
This page is one stock. Monday covers all of them.
MIST appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MIST vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Milestone Pharmaceuticals, Inc. returned −83.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MIST analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 8.7×
- Price / book
- 2.9×
- EV / EBITDA
- —
Cheaper than 13% of US stocks
Cheaper than 32% of US stocks
- Revenue growth (YoY)
- 134.9%
- Earnings growth (YoY)
- —
- Gross margin
- 94.3%
- Operating margin
- —
- Net margin
- —
Higher than 94% of US stocks
Higher than 98% of US stocks
- Return on equity
- −1370.6%
- Return on assets
- −45.7%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Milestone Pharmaceuticals, Inc. has a market value of $46.2M and an enterprise value of $50.7M.
Revenue in the twelve months to 30 June 2026: $2.3M.
Net income over the same four quarters: −$84.0M, a −3585.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$61.6M.
Milestone Pharmaceuticals, Inc. employs 38 people — $62K of revenue per employee.
Data provided by Twelve Data
MIST and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MIST’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Milestone Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MIST
What is the MIST stock price forecast for 2026-2027?
The median 12-month analyst price target for Milestone Pharmaceuticals, Inc. is $4, with estimates ranging from $1 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MIST stock a buy right now?
Of the 7 analysts covering Milestone Pharmaceuticals, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Milestone Pharmaceuticals, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MIST?
As at 21 Nov 2026, Milestone Pharmaceuticals, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (87 of 100).
Will MIST stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $4, and Ticker Nerd's factor model ranks Milestone Pharmaceuticals, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MIST stock forecast for 2030?
No analyst covering Milestone Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $6 over the next 12 months.
How has MIST stock performed over the past year?
Milestone Pharmaceuticals, Inc. returned -83.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Milestone Pharmaceuticals, Inc. do?
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for adults. Milestone Pharmaceuticals Inc.’s lead product, CARDAMYST (etripamil) nasal spray, is designed for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia, with additional development efforts in atrial fibrillation with rapid ventricular rate.
About Milestone Pharmaceuticals, Inc.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for adults. Milestone Pharmaceuticals Inc.’s lead product, CARDAMYST (etripamil) nasal spray, is designed for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia, with additional development efforts in atrial fibrillation with rapid ventricular rate. The company centers its work on self-administered therapies that can be used outside the emergency department, addressing episodic heart rhythm conditions through a nasal spray delivery format. Based in Montreal, Canada, Milestone Pharmaceuticals Inc. serves the cardiovascular and biotechnology markets through its current product portfolio and ongoing clinical and commercial activities in the United States and Canada.
CEO Mr. Joseph G. Oliveto M.B.A. · 38 employees · Canada · https://www.milestonepharma.com